Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc. announced today the Government of Quebec will continue to provide public funding of JARDIANCE® (empagliflozin), SYNJARDY® (a single-pill combination of empagliflozin and metformin), and TRAJENTA